Drug General Information (ID: DDI1JUYW52)
Drug Name			Pegaspargase		Drug Info		Norgestimate		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Contraceptive Agents
Structure

Mechanism of Pegaspargase-Norgestimate Interaction (Severity Level: Moderate)
Decreased metabolism due to hepatotoxicity Click to Show/Hide Mechanism Graph
Drug Name		Pegaspargase				Norgestimate
Mechanism		Hepatotoxicity				Metabolized by the liver
Key Mechanism Factor 1
		Factor Name		Hepatotoxicity
		Factor Description		Drug-induced hepatotoxicity is an acute or chronic liver injury secondary to drugs. The metabolism of drugs is reduced when the liver is damaged and fewer enzymes are synthesized by the liver.
Mechanism Description		Decreased metabolism of Norgestimate caused by Pegaspargase mediated hepatotoxicity

Recommended Action
Management		The use of oral contraceptives during asparaginase treatment is not recommended. Other non-oral contraceptive methods should be used in women of childbearing potential. According to the manufacturer, females of reproductive potential should be advised to use effective contraception during asparaginase treatment and for at least 3 to 6 months after the last dose.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Asparlas (calaspargase pegol). Servier, Boston, MA.